Related Experiment Video

Updated: Mar 10, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors

Hazel A Rogers1, Jasper Estranero1, Keshni Gudka1

  • 1Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham, UK.

Oncotarget
|December 8, 2016
PubMed

Insights

Targeting the phosphoinositide 3-kinase (PI3K) pathway offers a promising new strategy for treating pediatric central nervous system (CNS) tumors, the leading cause of cancer deaths in children. This review explores PI3K pathway alterations and inhibitors for pediatric CNS cancer treatment.

Area of Science:

  • Oncology
  • Pediatric Oncology
  • Molecular Biology

Background:

  • Central nervous system (CNS) tumors are the most common pediatric cancer and the leading cause of cancer-related mortality in children.
  • Aberrant activation of the phosphoinositide 3-kinase (PI3K) signaling pathway is frequently observed in pediatric CNS neoplasms.
  • The PI3K pathway plays a critical role in tumor growth, survival, migration, and enhancing treatment efficacy.

Purpose of the Study:

  • To review genetic alterations in the PI3K pathway in pediatric CNS tumors.
  • To examine the pathological role of PI3K signaling in these tumors.
  • To summarize preclinical and clinical data on PI3K pathway inhibitors for pediatric CNS cancer treatment.

Main Methods:

  • Review of large-scale profiling studies identifying PI3K pathway alterations.
  • Analysis of preclinical data on the role of PI3K signaling.
  • Summary of current clinical trial data for PI3K pathway inhibitors.

Main Results:

  • The PI3K pathway is a commonly activated target in pediatric CNS tumors.
  • PI3K signaling inhibition shows promise in preclinical models.
  • Clinical trials are evaluating PI3K inhibitors in pediatric cancer patients.

Conclusions:

  • Targeting the PI3K pathway represents a promising therapeutic strategy for pediatric CNS tumors.
  • Further investigation and clinical application of PI3K inhibitors are warranted.
Keywords:
PI3K pathwaybrain tumorcancerpediatrictherapy

More Related Videos

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.0K
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.6K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K